Table 1.
Characteristics of cGvHD patients and their clinical laboratory parameters.
| Characteristics of cGvHD patients | ||||
|---|---|---|---|---|
| Gender | Female, N (%) | 92 (43.2%) | ||
| Male, N (%) | 121 (56.8%) | |||
| Age (years), median (range) | 45 (5-71) | |||
| Time from transplantation until study participation (days), median (range) | 1136 (131-7746) | |||
| Time from transplantation until cGvHD diagnosis (days), median (range) | 233 (41-4325) | |||
| Time from cGvHD diagnosis until study participation (days), median (range) | 756 (0-6545) | |||
| Pre- and post-transplant information | N | % | ||
| Primary disease | Leukemia a | 138 | 64.8% | |
| Lymphoproliferative disease b | 60 | 28.2% | ||
| Other c | 15 | 7.0% | ||
| Myeloablative conditioning | Yes | 121 | 56.8% | |
| No | 89 | 41.8% | ||
| Unknown | 3 | 1.4% | ||
| Donor relation | Related | 128 | 60.1% | |
| Unrelated | 85 | 39.9% | ||
| Hematopoietic stem cells source | Bone marrow | 41 | 19.3% | |
| Peripheral blood | 166 | 77.9% | ||
| Umbilical blood | 6 | 2.8% | ||
| Previous acute GvHD | Yes | 141 | 66.2% | |
| No | 71 | 33.3% | ||
| Unknown | 1 | 0.5% | ||
| Characterization of cGvHD | N | % | ||
| cGvHD onset | De novo | 71 | 33.3% | |
| Progressive | 78 | 36.6% | ||
| Quiescent | 63 | 29.6% | ||
| Unknown | 1 | 0.5% | ||
| cGvHD classification | Classic | 183 | 85.9% | |
| Overlap | 27 | 12.7% | ||
| Unknown | 3 | 1.4% | ||
| Lines of systemic therapy, median (range) | 4 (0-9) | |||
| Clinician’s impression of activity d | Active | 101 | 47.4% | |
| Age (years), median (range) |
46.5 (5-71) | |||
| Non-active | 19 | 8.9% | ||
| Age (years), median (range) |
25 (7-66) | |||
| Unknown | 93 | 43.7% | ||
| Intensity of imunosupression | None/Mild | 64 | 30.0% | |
| Moderate/High | 149 | 70.0% | ||
| Activity by therapeutic intent at the time of evaluation | Non-active | 72 | 33.8% | |
| Active | 93 | 43.7% | ||
| Unknown/Not applicable e | 48 | 22.5% | ||
| Organs involved with cGvHD | Skin | 163 | 76.5% | |
| Mouth | 141 | 66.2% | ||
| Eyes | 166 | 77.9% | ||
| Liver | 111 | 52.1% | ||
| Gastrointestinal tract | 92 | 43.2% | ||
| Lungs | 164 | 77.0% | ||
| Joints/fascia | 130 | 61.0% | ||
| Genital tract (for women) | 53 | 57.6% | ||
| Global cGvHD NIH score | Mild | 4 | 1.9% | |
| Moderate | 52 | 24.4% | ||
| Severe | 157 | 73.7% | ||
| Number of involved organs with cGvHD, median (range) |
5 (1-8) | |||
| Laboratory parameters | ||||
| Parameter | Median (range) | Parameter | Median (range) | |
| Erythrocyte sedimentation rate (mm/h) | 16 (1-113) | Beta 2 microglobulin (mg/L) | 2.10 (0.9-70.74) | |
| Eosinophils (x10^9 /L) | 0.08 (0-91.07) | C3 (g/L) | 1.35 (0.64-2.22) | |
| Platelets (x10^9 /L) | 251 (24-663) | C4 (g/L) | 0.28 (0.13-7.39) | |
| Total proteins (g/L) | 65 (45-89) | IgG (g/L) | 6.55 (0.98-33.8) | |
| Albumin (g/L) | 37 (21-300) | IgA (g/L) | 0.63 (0.05-4.81) | |
| CRP (mg/L) | 18.75 (1.6-1600) | IgM (g/L) | 0.63 (0.06-6.47) | |
a
Includes: acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myeloid leukemia and myelofibrosis.
b
Includes: Hodgkin's and non-Hodgkin's lymphoma, chronic lymphocytic leukemia and multiple myeloma.
c
Includes: sarcomas and immunodeficiencies, aplastic anemia, paroxysmal nocturnal hemoglobinuria and other diagnoses.
d
Clinician’s impression of disease activity was recorded for 120 patients.
e
Patients either did not receive any immunosuppressive therapy or did not meet any of criteria or alter therapy due to toxicity.